We have increased the size of the KSI-101 MESI pivotal program 64 Pivotal analysis 1 (n=300) n=900 KSI-101 MESI Pivotal Program (PEAK and PINNACLE) • Patient enrollment faster than expected • No major changes to expected timelines are anticipated • Pivotal program aligned with FDA in type C meeting First 300 patients from PEAK Last 300 patients from PEAK + PINNACLE patients Pivotal analysis 2 (n=600) Primary Endpoint Readout: 4Q 2026 Primary Endpoint Readout: 2Q 2027